HCW Biologics approves 1-for-40 reverse stock split to regain Nasdaq compliance

HCW Biologics Inc.

Reverse split effective April 11, 2025; outstanding shares reduced from ~44.9M to ~1.12M.
Purpose: raise bid price above $1.00 to regain compliance with Nasdaq Listing Rule 5810(c)(3)(A).
Authorized shares remain 250M; no change to par value ($0.0001).
Fractional shares rounded up; CUSIP changes to 40423R204.
Stockholders approved at special meeting March 31, 2025; board acted same day.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

HCW Biologics Inc.: Filed Certificate of Amendment of Certificate of Incorporation to effect a 1-for-40 reverse stock split, with an effective date of April 11, 2025 (effective 2025-04-11).

Change: charter amendment
Effective: 2025-04-11

Exact text from the filing

The Company effected the Reverse Stock Split pursuant to the Company’s filing of an Certificate of Amendment of Certification of Incorporation with the Secretary of State of the State of Delaware on March 31, 2025

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-048619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.